8-K/A: Aditxt and Evofem Revive Merger Agreement with Fourth Amendment After Initial Termination

Aditxt and Evofem have reinstated their merger agreement, previously terminated due to a missed payment, with a new amendment that includes a $1 million payment and revised investment terms.

Summary

• Aditxt and Evofem have reinstated their merger agreement after it was terminated due to Aditxt's failure to make an initial equity investment by April 1, 2024.
• The reinstatement is formalized through a Fourth Amendment to the original merger agreement, dated May 2, 2024.
• As part of the reinstatement, Aditxt has agreed to make an initial payment of $1 million to Evofem.
• The amendment modifies the original agreement, including the removal of the 'no-shop' provision, allowing Evofem to seek other investment opportunities.
• Aditxt is now required to purchase Evofem's Series F-1 Preferred Stock, with a maximum aggregate amount of $2.5 million, based on 40% of the gross proceeds from each subsequent capital raise by Aditxt.
• The timeline for the merger has been extended, with a new termination date of July 15, 2024.
• Evofem can terminate the agreement if the initial $1 million payment is not received by May 3, 2024, if $1.5 million of the Parent Capital Raise is not paid by June 17, 2024, if $1 million of the Parent Capital Raise is not paid by July 1, 2024, or if Aditxt fails to make payments within five days of each subsequent capital raise.

Sentiment

Score: 4

Explanation: The document indicates a troubled merger process with an initial termination and subsequent reinstatement. While the deal is back on, the missed payment and revised terms suggest underlying financial and execution risks. The removal of the 'no-shop' clause also indicates a weaker position for Aditxt.

Positives

• The merger agreement has been reinstated, preserving the potential for the merger to proceed.
• Evofem receives an immediate $1 million payment from Aditxt.
• Evofem is now free to explore other investment opportunities due to the removal of the 'no-shop' provision.
• The revised payment structure for Aditxt's investment is tied to their capital raises, potentially aligning interests.

Negatives

• The merger agreement was initially terminated due to Aditxt's failure to make the initial equity investment.
• The reinstatement required a $1 million payment from Aditxt, indicating a potential financial strain.
• The merger timeline has been extended, introducing further uncertainty.
• Evofem has the right to terminate the agreement if Aditxt fails to meet specific payment deadlines, creating a risk of further delays or termination.

Risks

• Aditxt may face challenges in raising the required capital to meet the investment obligations.
• Evofem could terminate the agreement if Aditxt fails to meet the payment deadlines.
• The extended timeline for the merger introduces uncertainty and potential for further delays.
• The removal of the 'no-shop' provision could lead to Evofem pursuing alternative deals, potentially jeopardizing the merger.

Future Outlook

The merger is contingent on Aditxt successfully raising capital and meeting the payment deadlines. The agreement can be terminated by Evofem if these conditions are not met. The removal of the 'no-shop' clause allows Evofem to explore other options, adding uncertainty to the merger's future.

Management Comments

• The parties mutually desire to reinstate the Merger Agreement and to amend the Merger Agreement as provided below.
• The Company hereby waives both the Parents non-compliance with Section 6.10 of the Merger Agreement in full on behalf of itself and on behalf of any other persons entitled to such rights.

Industry Context

Merger agreements in the biotech and pharmaceutical sectors often involve complex financial arrangements and are subject to regulatory and market risks. The reinstatement of this agreement after a termination highlights the volatility and challenges in these types of transactions. The removal of the 'no-shop' clause is not uncommon when a deal is at risk of falling apart.

Comparison to Industry Standards

• The initial termination of the merger agreement due to a missed payment is unusual, as most deals have mechanisms to avoid such a situation.
• The reinstatement of the agreement with revised terms is not uncommon, as parties often renegotiate to salvage a deal.
• The removal of the 'no-shop' clause is a significant concession by Aditxt, indicating a weaker negotiating position.
• The requirement for Aditxt to purchase preferred stock based on a percentage of their capital raises is a common structure in biotech mergers, aligning the interests of both parties.
• The extended timeline for the merger is not unusual, as these deals often require time to complete due diligence and secure financing.

Stakeholder Impact

• Shareholders of both Aditxt and Evofem face uncertainty due to the initial termination and subsequent reinstatement of the merger agreement.
• Employees of both companies may experience uncertainty regarding their future employment.
• Creditors of both companies may be impacted by the financial implications of the merger and its revised terms.

Next Steps

• Aditxt needs to secure funding to meet the payment obligations by June 17, 2024 and July 1, 2024.
• Evofem may explore other investment opportunities due to the removal of the 'no-shop' provision.
• The parties need to work towards completing the merger by the new termination date of July 15, 2024.

Key Dates

Keywords

merger agreement, reinstatement, amendment, capital raise, equity investment, termination, Evofem Biosciences, Aditxt, preferred stock, payment